title: Clozapine reinitiation following a "red result" secondary to chemotherapy.
abstract: We describe a case of a patient whose clozapine was discontinued after a "red result" following R-CHOP (rituximab with cyclophosphamide, hydroxydaunorubicin, Oncovin, and prednisolone) chemotherapy for large B-cell lymphoma. In some cases, manufacturers grant permission, on compassionate grounds, for clozapine to be continued or reinitiated following assessment by their consultant hematologist. Other than a recent case report, there is not much literature surrounding this medical issue. However, since the two leading causes of mortality in schizophrenia are cancer and cardiac disease, this is not an uncommon occurrence. Clinicians are reluctant to prescribe clozapine in view of its side-effect profile, despite its proven efficacy for managing treatment-resistant schizophrenia. The alternative is to prescribe two antipsychotics to manage symptoms. This approach may be associated with increased side effects, and evidence for actual benefits is scant. The consequences were disastrous in this case, as the individual not only relapsed following clozapine discontinuation, but the therapy for this treatable form of lymphoma had to be delayed. He was eventually admitted to an inpatient unit after having been stable for 15 years. We managed to stabilize him with olanzapine and aripiprazole which enabled the heme-oncology group to resume R-CHOP therapy with filgrastim (granulocyte colony-stimulating factor). Even so, he continued to exhibit severe psychotic symptoms, with religious delusions and auditory hallucinations. We therefore applied for permission to rechallenge him on clozapine. Permission was granted when protocol conditions were met, and reinitiation went without any adverse events. The patient's symptoms showed improvement within a few weeks, and the other antipsychotics were discontinued once clozapine was titrated up to 300 mg. The decision to reinitiate clozapine following a red result is not to be taken lightly, but needs to be considered in terms of the risks versus benefits. More literature surrounding this issue would be of great benefit to clinicians, patients, and their families.
authors.affiliation: Department of Psychiatry, Kingston General Hospital, Kingston, ON, Canada.
authors.forename: Tariq
authors.initials: T
authors.lastname: Munshi
authors.forename: Mir
authors.initials: M
authors.lastname: Mazhar
authors.forename: Tariq
authors.initials: T
authors.lastname: Hassan
keywords: R-CHOP chemotherapy; clozapine agranulocytosis; clozapine discontinuation; clozapine rechallenge; red result
references.citation: Psychooncology. 2013 Jul;22(7):1674-5
references.pmid: 23059755
references.citation: J Clin Psychiatry. 1999;60 Suppl 12:47-50
references.pmid: 10372612
references.citation: J Clin Psychiatry. 2003 Jan;64(1):30-4
references.pmid: 12590620
references.citation: Psychosomatics. 1999 Sep-Oct;40(5):414-21
references.pmid: 10479946
references.citation: Psychiatry (Edgmont). 2007 Oct;4(10):23-9
references.pmid: 20428308
references.citation: Br J Psychiatry. 2006 Mar;188:255-63
references.pmid: 16507968
references.citation: Am J Psychiatry. 2008 Jul;165(7):813-8
references.pmid: 18593787
references.citation: Psychiatr Serv. 1996 Jan;47(1):52-6
references.pmid: 8925346
references.citation: Ann Pharmacother. 2008 Jun;42(6):852-60
references.pmid: 18477732
references.citation: Am J Psychiatry. 1999 Jul;156(7):990-9
references.pmid: 10401441
references.citation: Drug Saf. 1992;7 Suppl 1:51-6
references.pmid: 1503678
references.citation: Br J Psychiatry. 1996 Feb;168(2):217-20
references.pmid: 8837913
references.citation: Psychopharmacol Bull. 1989;25(1):57-62
references.pmid: 2772119
references.citation: Am J Psychiatry. 2011 Oct;168(10):1120
references.pmid: 21969051
references.citation: Pharmacopsychiatry. 2004 Mar;37 Suppl 1:S70-8
references.pmid: 15052517
references.citation: N Engl J Med. 1993 Jul 15;329(3):162-7
references.pmid: 8515788
references.citation: Epidemiology. 1997 Nov;8(6):671-7
references.pmid: 9345668
references.citation: BMJ. 2013 May 21;346:f2539
references.pmid: 23694688
references.citation: Pharmacogenetics. 2001 Mar;11(2):135-41
references.pmid: 11266078
references.citation: Psychopharmacology (Berl). 1989;99 Suppl:S113-7
references.pmid: 2682726
references.citation: Br J Psychiatry. 2011 Apr;198(4):247-9
references.pmid: 21972272
references.citation: Schizophr Res. 2012 Feb;134(2-3):180-6
references.pmid: 22113154
references.citation: J Clin Psychopharmacol. 2004 Dec;24(6):613-7
references.pmid: 15538122